Supplementary Materials

Supplementary Material for:

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

Beth D. Kirkpatrick, Stephen S. Whitehead, Kristen K. Pierce, Cecilia M. Tibery, Palmtama L. Grier, Noreen A. Hynes, Catherine J. Larsson, Beulah P. Sabundayo, Kawsar R. Talaat, Anna Janiak, Marya P. Carmolli, Catherine J. Luke, Sean A. Diehl, Anna P. Durbin*

*Corresponding author. E-mail: adurbin1{at}jhu.edu

Published 16 March 2016, Sci. Transl. Med. 8, 330ra36 (2016)
DOI: 10.1126/scitranslmed.aaf1517

This PDF file includes:

  • Fig. S1. Components of the LATV dengue vaccines TV003 and CYD (Dengvaxia).
  • Table S1. Incidence of specific AEs in TV003 recipients compared to controls.
  • Table S2. Interval between TV003 and challenge.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Other supplemental material S1 (Microsoft Word format). Clinical protocol for the study “A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection with Attenuated DENV-2, rDEN2Δ30-7169.”
  • Other supplemental material S1 (Microsoft Word format). Consent form for the study “A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection with Attenuated DENV-2, rDEN2Δ30-7169.”
  • Other supplemental material S2. Excel file of screening and enrollment data.

[Supplementary Files S1 to S2]